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Abstract
Background
In Coˆte d’Ivoire, people living with HIV (PLHIV) have free access to antiretroviral therapy
(ART) and cotrimoxazole. Yet, they may use other medications to treat non-HIV diseases.
Scarce data are available regarding the use of non-HIV medications in Africa. This study
describes the use of non-HIV medications and identifies the factors associated with their
use by PLHIV on ART in Coˆte d’Ivoire.
Methods
A cross-sectional study was conducted in six HIV clinics in 2016. HIV-1-infected adults
receiving ART for at least one year were eligible. A standardized questionnaire was used to
collect demographics, HIV characteristics and medication use data. Associated factors
were identified using a multivariate adjusted Poisson regression.
Results
A total of 1,458 participants (74% women) were enrolled. The median age was 44 years,
and the median duration of ART was 81 months. A total of 696 (48%) participants reported
having used at least one non-HIV medication. Among the 1,519 non-HIV medications used,
550 (36%) had not been prescribed and 397 (26%) were from the nervous system class.
Individuals who were more likely to report the use of at least one non-HIV medication
included those who had been treated in an Abidjan HIV clinic, had a high school education
level, had a monthly income between 152 and 304 euros, had a poor perceived health sta-
tus, had WHO advanced clinical stage, had used traditional medicine products and had not
used cotrimoxazole.
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Conclusion
Almost half PLHIV on ART reported using non-HIV medication. Further research is needed
to assess whether the use of non-HIV medication is appropriate given about a third of those
medications are not being prescribed.
Introduction
The successful scale-up of antiretroviral therapy (ART) during the last two decades has changed
the face of the HIV epidemic, with HIV infection now being considered a chronic disease [1]. Ade-
quate treatment has led to reductions in AIDS-related mortality and morbidity [2, 3] and has also
improved the life expectancy of people living with HIV (PLHIV), which is now almost identical to
the life expectancy observed in the general population [4–6]. Nevertheless, increased life expec-
tancy and aging come with new challenges in HIV management. In addition to AIDS-related dis-
eases, PLHIV are exposed to non-HIV diseases that occur independently of the weakness of the
immune system [7, 8]. Non-HIV diseases are mostly chronic diseases [7, 9–12]; yet, PLHIV in
Africa also suffer from acute diseases, such as malaria and respiratory infections [13, 14].
In resource-limited countries, the Word Health Organization (WHO) recommends the ini-
tiation of an ART with a cotrimoxazole prophylaxis for every PLHIV [15]. In Coˆte d’Ivoire,
ART is accessible nation-wide [16] and is free of charge in public pharmacies [17–19]. This is
not the case for the therapeutic management of non-communicable diseases, such as diabetes,
hypertension and cancer.
In low-income countries, non-HIV medications may be purchased with or without a pre-
scription. Taking non-HIV medications without a prescription depends on many factors, such
as previous successful experiences with the same or similar medications, the cost of non-HIV
disease management [19, 20], non-HIV essential medications not usually being available in
public health care settings [20], the accessibility of health facilities [21–24], insufficient health
insurance coverage [25, 26] and perceiving that the disease is not serious [21–24]. When the
use of non-prescribed medications is unjustified and inappropriate, there is an increased risk
of drug-drug interactions [27, 28], medication resistances, undesirable side effects and
increased health expenditures [29, 30].
There is limited information on the use of non-HIV medications among PLHIV. To our
knowledge, seven studies have focused on the use of non-HIV medications among PLHIV in
Africa [19, 26, 31–34]. In three of those studies, non-HIV medications were only listed [26, 32,
33], and in another one, the focus was on the cost of non ARV medications [19]. Only two stud-
ies, one from Senegal [31] and the other from South Africa [34], reported the proportions of
PLHIV on ART who used at least one non-HIV medication (85% and 87%, respectively). In
these studies, the patients included were on ART less than one year and data was not available on
non HIV medication. Moreover, no distinction was made between non-HIV prescribed medica-
tions and non-HIV non-prescribed medications. To our knowledge, the use of non-HIV medica-
tions either prescribed or not has not been comprehensively studied in Africa. Our study aimed
to describe the use of non-HIV medications among PLHIV on ART for at least 12 months in
Coˆte d’Ivoire and to identify factors associated with the use of at least one non-HIV medication.
Materials and methods
Study design and settings
A cross-sectional study was conducted from April 11th to September 28th, 2016, in six HIV
clinics of Coˆte d’Ivoire. Three of these clinics were located in Abidjan, the economic capital,
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one in San Pedro in the South-west of the country, one in Bouake´ in the Center of the country
and the last in Korhogo in the North. These cities were selected in regions with high HIV prev-
alence. In Abidjan, the three largest HIV clinics were selected. In the three other regions, we
selected the clinic with the largest number of PLHIV.
Study population and enrollment of patients
The study population included individuals living with HIV-1, aged 18 years or older, receiving
ART for at least one year. Every day during the study period, all eligible individuals attending
the participating HIV clinics for a routine follow-up visit were offered to participate in the
study. After confirming their eligibility in the medical patient record, the site investigator pro-
vided clear information on the study, discussed the information sheet with the participant and
fixed an appointment for those who agreed to participate. Three days before the appointment
date, each participant received a reminder call from a social worker to confirm the time of the
interview.
Data collection
On the day of interview, the participant signed the consent form before the interview began.
During the interview, a social worker collected each participant’s demographics and HIV char-
acteristics (WHO clinical stage, history of CD4 count, clinical events, ART regimen and other
treatments) using a standardized questionnaire formatted as a case report file (CRF). Data on
all medications and traditional and complementary medicine (TCM) products used during
the preceding 30 days were also collected. To help in identifying medications used, participants
were asked to bring all medications they used. For participants who did not bring their medi-
cations, a photo library was shown to help them identify medications they were using. A phar-
macist analyzed pictures of all the material brought by the participants (containers,
prescription forms, and products) to determine the names, formulations and doses of all medi-
cations used by the participants.
Outcome variable
The main outcome was the use of at least one non-HIV medication. Participants were consid-
ered to use at least one non-HIV medication if they reported using any medication other than
antiretroviral medications and cotrimoxazole.
Independent variables
Patient-related variables included demographic characteristics such as age, sex, have a signifi-
cant other, education level, being employed or not, monthly income in euros and health insur-
ance coverage. In the context of HIV infection, the term “older” refers to patients aged� 50
years [35, 36]. A participant was considered to have health insurance coverage if he/she
reported having medical or/and pharmaceutical insurance coverage. Region was defined
according to the localization of the recruiting HIV center: economic capital (for clinics in Abi-
djan) or hinterland (for clinics in Bouake´, San Pedro and Korhogo).
Health-related variables consisted of data on perceived health status, alcohol consumption
and HIV characteristics. Perceived health status was measured using a 6-level Likert scale
(excellent to poor). Perceived health status was considered “at least acceptable” when the
response was either excellent, very good, good or acceptable; otherwise, it was considered
“poor”. Alcohol consumption was measured using questions from the WHO STEPS question-
naire (37). Two categories were defined. Alcohol users were those who reported they had used
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alcohol in the 30 days prior to the interview. The following HIV characteristics were abstracted
from the medical records: the date of HIV diagnosis, the initial CD4 count in cells/mm3
(< 200, 200–349, 350–499,� 500), and the WHO clinical stage at diagnosis. The duration of
HIV infection was the number of months between the date of HIV diagnosis and the date of
the interview.
Concerning treatment-related variables, we measured the use of HIV and non-HIV medi-
cations along with traditional and complementary medicines. For HIV medications, current
use of ART and cotrimoxazole was abstracted from medical records. ART was classified into
two categories: first-line ART (either three nucleoside reverse transcriptase inhibitors or two
nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibi-
tor) and second- or third-line ART (two nucleoside reverse transcriptase inhibitors with a pro-
tease inhibitor or with an integrase inhibitor) [37, 38]. The duration of ART in months was
defined as the time between the date of ART initiation and the date of the interview. Each par-
ticipant was asked to report the number of ART pills taken each day. Finally, participants were
considered to have used a TCM product if they reported having used a TCM within the last 30
days. TCM products were from two main TCM therapeutic modalities: 1) TCM consisting of
spiritual and manual treatments, 2) TCM consisting of herbal medicines, veterinary medicines
and / or mineral medicines [39].
Non-HIV medications were classified according to the WHO Anatomical Therapeutic
Chemical Classification (ATC) system [40]. For each non-HIV medication, the pharmacologi-
cal classes were determined. Medications that could not be identified due to a lack of informa-
tion (such as medications bought in a public market and medications with information
written only in Arabic or Chinese) were coded 99999. Natural products that did not have a
code in the ATC classification were coded 88888. When a drug had more than one ATC code,
we used the code relevant to the self-reported illness. For the choice of ATC codes for generic
medications whose International Common Denominations (ICDs) were difficult to identify,
we used the national list of the reimbursable medications from ministry of health that contains
generic medication names associated with the ICDs for medications.
Participants were considered to have used a TCM product if they reported having used a
TCM within the last 30 days.
Statistical analysis
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Pearson
Chi square tests were used to compare proportions, Student’s t-tests were used to compare
means and Wilcoxon tests were used to compare medians. Factors associated with the use of at
least one non-HIV medication were identified using a multivariate Poisson regression model.
We calculated prevalence ratios (PRs) with their 95% confidence intervals (CIs) (32). To build
the model, we included all variables associated with the use of at least one non-HIV medication
in the unadjusted analysis (P< 0.2) and used the backward method to identify only variables
independently predictive of the use of at least one non-HIV medication with a P-value < 0.05.
Sex and age were forced into the final model (33, 34).
Ethical consideration
Before being enrolled in the study, each participant received clear information and provided
written consent to participate, including the authorization to use personal data for research
purposes. The study was approved by the National Ethics Committee for Research in Coˆte
d’Ivoire and the ethics in research committee of CHU de Quebec-Universite´ Laval.
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Results
A total of 1,729 HIV patients were approached to participate in the study. Among them, 1,458
(84%) agreed and were included. The reasons for non-participation are summarized in
Table 1.
Characteristics of the participants according to the region where they were recruited are
presented in Table 2. They had a median age of 44 years, IQR (38–50), 27% were aged� 50
years and 736 (50%) were recruited in Abidjan. Approximately 75% of the participants were
women. Among the participants, 145 (10%) had health insurance coverage, of which 82% lived
in Abidjan. In addition, 776 (53%) reported having used at least one TCM product in the 30
days preceding the interview. Participants attending an HIV clinic in Abidjan had a higher
level of education and a higher income than the participants attending a hinterland HIV
center.
HIV medications use
The median ART duration was 81 months (IQR: 47–110), with most participants (n = 1,182;
81%) on a first-line ART regimen. The median number of ART pills taken daily was 2 (IQR:
2–3), with 263 (18%) participants taking� 5 ART pills. A total of 535 (37%) patients reported
using cotrimoxazole in addition to ART, with the proportion of PLHIV using cotrimoxazole
being higher in Abidjan than in the hinterland (48% vs. 25%, P =<0.0001).
Non-HIV medications use
A total of 696 (48%) participants reported using at least one non-HIV medication. Among
them, 319 (46%) reported using one medication, 169 (24%) two medications, 95 (14%) three
medications and 113 (16%)� four medications. The median number of non-HIV medications
per person was two (IQR: 1–3). Among users of non-HIV medications, 284 (41%) used only
non-prescribed medications (median: 1; IQR: 1–2), 318 (46%) used only prescribed medica-
tions (median: 2; IQR: 1–3) and 94 (13%) used both prescribed and non-prescribed medica-
tions (median: 3; IQR: 2–5). Concerning non-communicable disease, the proportions of users
of non-HIV medications for the treatment of cardiovascular disease and diabetes were 5%
(N = 68), and 1.1% (N = 16), respectively.
Table 1. Frequency of reported reasons to decline participation (N = 271).
Reasons N %
Were unavailable for the interview 88 32.5
Could not be reached 41 15.1
Gave no reason to decline participation 20 7.4
Were not interested by the study 20 7.4
Were outside the city during the study period 19 7.0
Did not come to the interview 19 7.0
Either had or a family member had already participated in another study 14 5.2
Did not use modern and traditional medicine 13 4.8
Were not called to make an appointment 9 3.3
Had other reasons� 28 10.3
Total 271 100
� accident, need approbation from family, fear of breaking confidentiality, financial difficulties
https://doi.org/10.1371/journal.pone.0221335.t001
Use of non-HIV medication among people living with HIV and receiving antiretroviral treatment in Coˆte d’Ivoire
PLOS ONE | https://doi.org/10.1371/journal.pone.0221335 September 16, 2019 5 / 17
Table 2. Characteristics of the 1458 participants according to the recruitment setting.
Characteristics Total
N = 1458
Abidjan HIV
clinics
N = 736
Hinterland
HIV clinics
N = 722
Pearson chi-squared (χ2) test$/ Wilcoxon test£
N % n % n % P values
Patient-related
Age (years)
Median [IQR] 44 [38–50] 44 [39–51] 44 [37–50] 0.048
< 50 years 1070 73.4 525 71.9 541 74.9 00.18
� 50 years 388 26.6 207 28.1 181 25.1
Sex
Men 381 26.1 198 26.9 183 25.3 0.499
Women 1077 73.9 538 73.1 539 74.7
Body Mass index
Underweight (< 18.5) 165 11.3 71 09.6 94 13.0 <0.0001
Normal weight (18.5–24.99) 796 54.6 373 50.7 423 58.6
Overweight (25–29.99) 359 24.6 205 27.9 154 21.3
Obese (� 30) 138 09.5 87 11.8 51 07.1
Have a significant other
Yes 726 49.8 360 48.9 366 50.7 0.496
No 732 50.2 376 51.1 356 49.3
Education
No school 454 31.1 142 19.3 312 43.4 <0.0001
Primary level 433 29.7 217 29.5 216 29.7
High school 470 32.2 290 39.4 180 24.9
> High school 101 6.93 87 11.8 14 01.9
Employment
Yes 1179 80.9 620 84.2 559 77.4 0.0009
No 279 19.1 116 15.8 163 22.6
Monthly income in euros <0.0001
< 92 964 66.1 364 49.4 600 83.1
92–151 235 16.1 183 24.9 52 07.2
152–304 148 10.2 105 14.3 43 06.0
� 304 90 06.2 79 10.7 11 01.5
Don’t Know 21 01.4 05 00.7 16 02.2
Health insurance coverage
Yes 145 10.0 119 16.2 26 03.6 <0.0001
No 1313 90.0 617 83.8 163 96.4
Health related
Perceived Health Status
At least acceptable 1166 80.0 610 82.9 556 77.0 0.0038
Poor 281 19.3 120 16.3 161 22.3
Missing data 11 00.7 06 00.8 05 00.7
Hospitalization in the year before interview
Yes 116 09.9 63 08.6 53 07.3 00.39
No 1313 90.1 673 91.4 696 92.7
Alcohol consumption
Yes 361 24.8 284 38.6 77 10.7 <0.0001
No 1096 75.2 451 61.4 645 89.3
HIV duration (months); median [IQR] 91 [57–120] 95 [58–129] 87 [55–113] <0.0001
� 120 1096 75.2 511 69.4 585 81 <0.0001
>120 362 24.8 225 30.6 137 19
(Continued)
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Pharmacologic classes of non-HIV medications
Overall, the number of non-HIV medications reported to be used by the 696 participants
totaled 1,519 (Table 3), of which 969 (64%) were prescribed. Among the 1,519 reported
non-HIV medications, 397 (26%) were from the nervous system class (reported by 349
Table 2. (Continued)
Characteristics Total
N = 1458
Abidjan HIV
clinics
N = 736
Hinterland
HIV clinics
N = 722
Pearson chi-squared (χ2) test$/ Wilcoxon test£
N % n % n % P values
Antiretroviral treatment (ART) duration (months); median [IQR] 81 [47–110] 82 [47–116] 80 [44–113] <0.0001
� 120 1206 82.7 570 77.4 636 88.1 <0.0001
>120 252 17.3 166 22.6 86 11.9
Initial CD4 count in cells/mm3; median [IQR]
< 200 685 47.0 319 43.3 366 50.7 0.0001
200–349 393 27.0 198 26.9 195 27.0
350–499 218 14.9 138 18.8 80 11.1
� 500 138 09.5 78 10.6 60 08.3
Missing data 24 01.6 03 00.4 21 02.9
N % n % n % P values
WHO clinical stage
I 535 36.7 255 34.6 280 38.8 <0.0001
II 521 35.7 187 25.4 334 46.3
III or IV 380 26.1 276 37.5 104 14.4
Missing data 01 0.1 00 00 01 0.1
Data not available 21 1.4 18 2.4 03 0.4
Treatment-related
ART regimen <0.0001
3 NRTIs§ / NNRTIsμ+2 NRTIs 1182 81.1 538 73.1 644 89.2
Others 276 18.9 198 26.9 78 10.8
Daily ART pills median [IQR] 02 [1–10] 02 [1–5] 02 [2–3] <0.0001
1 284 19.5 206 28.0 78 10.8 <0.0001
2 650 44.6 203 27.6 447 61.9
[3–4] 261 17.9 139 18.9 122 16.9
� 5 263 18.0 188 25.5 75 10.4
Use of cotrimoxazole
Yes 535 36.7 353 48.0 182 25.2 <0.0001
No 923 63.3 383 52.0 540 74.8
Use of traditional and complementary products
Yes 776 53.2 365 49.6 411 56.9 0.005
No 682 46.8 371 50.4 311 43.1
Use at least one non-HIV medication <0.0001
Yes 696 47.7 400 54.3 296 41.0
No 762 52.3 336 45.7 426 59.0
£Pearson Chi square tests were used to compare proportions
$Wilcoxon tests were used to compare medians
§NRTIs nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)
μ NNRTIs Non-nucleoside Reverse Transcriptase Inhibitor, IQR: interquartile Range.
https://doi.org/10.1371/journal.pone.0221335.t002
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Table 3. Anatomical, Therapeutic and Chemical (ATC) classification of non-HIV medications used according to whether or not they were prescribed.
Total
(N = 1519)
Medication prescribed
(n = 969)
Medication not
prescribed
(n = 550)
N % n % n %
A: Alimentary tract and metabolism 260 17.12 162 18.18 78 14.18
A01: Stomatological preparations 07 0.46 07 0.31 00 0.00
A02: Medications for acid related disorders 33 2.17 24 2.48 09 1.64
A03: Drugs for functional gastrointestinal disorders 13 0.86 11 1.14 02 0.36
A04: Antiemetic and antinauseants 02 0.13 02 0.21 00 0.00
A05: Bile and live therapy 04 0.26 04 0.41 00 0.00
A06: Drugs for constipation 03 0.20 02 0.21 01 0.18
A07: Antidiarrheal, intestinal anti-inflammatory/anti-infective agents 09 0.59 07 0.72 02 0.36
A10: Medications used in diabetes 20 1.32 20 2.06 00 0.00
A11: Vitamins 60 3.95 41 4.2 19 3.45
A12: Mineral supplements 88 8.79 49 5.06 39 7.09
B: Blood and blood forming organs 61 4.02 53 5.47 08 1.45
B01: Antithrombotic agents 04 0.26 03 0.31 01 0.18
B03: Anti-anemic drugs 57 3.75 50 5.16 07 1.27
C: Cardiovascular system 79 5.20 72 7.93 07 1.27
C01: Cardiac therapy 07 0.46 06 0.62 10 0.18
C02: Antihypertensive 04 0.26 02 0.21 02 0.36
C03 Diuretics 05 0.33 05 0.52 00 00
C05: Vasoprotectives 07 0.46 05 0.52 02 0.36
C07: Beta blocking agents 12 0.79 12 1.24 00 0.00
C08: Calcium channel blockers 10 0.66 10 1.03 00 0.00
C09: Agents acting on the renin (angiotensin system) 24 1.58 24 2.48 00 0.00
C10: Lipid modifying agents 10 0.66 08 0.83 02 0.36
D: Dermatologic drugs 24 1.58 18 1.86 6 1.09
D01: Antifungals for dermatological use 06 0.39 05 0.52 01 0.18
D02: Emollients and protectives 01 0.07 01 0.10 00 0.00
D06: Antibiotics and chemotherapeutics for dermatological use 02 0.13 01 0.10 01 0.18
D07: Topical dermatological corticosteroids 09 0.59 06 0.62 03 0.55
D08: Antiseptics and disinfectants drugs 03 0.20 03 0.31 00 0.00
D10: Anti-acne preparations 01 0.07 0 0.00 01 0.18
D11: Other dermatological preparations 02 0.13 2 0.21 00 0.00
G: Genitourinary system and reproductive hormones 24 1.58 19 1.96 05 0.91
G01: Gynecological anti-infectives and antiseptics 09 0.59 07 0.72 02 0.36
G03: Sex hormones and modulators of the genital system 14 0.92 11 1.14 03 0.55
G04: Urologicals 01 0.07 01 0.10 00 0.00
H: Systemic hormonal preparations, excluding reproductive hormones and insulins 10 0.66 09 0.93 01 0.18
H02: Corticosteroids systemic 10 0.66 09 0.93 01 0.18
J: Anti-infectives for systemic use 144 9.48 97 10.01 47 8.55
J01: Antibacterial drugs 135 8.89 88 9.08 47 8.55
J02: Antimycotic drugs 07 0.46 07 0.72 00 0.00
J05: Antivirals for systemic use 02 0.13 02 0.21 00 0.00
M: Musculoskeletal system 114 7.50 68 7.02 48 8.36
M01: Anti-inflammatory and antirheumatic drugs 100 6.58 56 5.78 44 8.00
M02 Topical products for joint and muscular pain 04 0.26 03 0.31 01 0.18
M03: Muscle relaxants 08 0.53 07 0.72 01 0.18
(Continued)
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(24%) participants), and 260 (17%) were from the alimentary tract and metabolism class
(reported by 214 (15%) participants). Among the 550 non-HIV non-prescribed medica-
tions, 210 (38%) were analgesics, with the majority being non-opioid medications (used by
177 (12%) participants), along with 47 (9%) antibacterial medications (used by 43 (3%) par-
ticipants) and 44 (8%) anti-inflammatory and anti-rheumatic medications (used by 41 (3%)
participants).
Factors associated with the use of at least one non-HIV medication
In the multivariate Poisson regression, after adjusting for age and sex, seven factors were statis-
tically associated with the use of non-HIV medication (Table 4). Individuals who had a high
school education level (PR = 1.17 [95% CI = 1.02–1.35] vs. unschooled), a monthly income
between 152 and 304 euros (PR = 1.31 [95% CI = 1.12–1.53] vs.< 92euros), a poor (vs. at least
acceptable) perceived health status (PR = 1.30 [95% CI = 1.06–1.46]), a WHO clinical stage II
or III/IV (PR = 1.24 [95% CI = 1.08;1.41]; PR = 1.22 [95% CI = 1.06;1.40]), and those who
were TCM product users (vs. no (PR = 1.22 [95% CI = 1.10–1.37]) were more likely to report
the use of at least one non-HIV medication. Participants recruited in a hinterland HIV clinic
(PR = 0.72 [95% CI = 0.64–0.82]) and cotrimoxazole users (vs. not) (PR = 0.77 [95%
CI = 0.67–0.84]) were less likely to report the use at least one non-HIV medication.
Table 3. (Continued)
Total
(N = 1519)
Medication prescribed
(n = 969)
Medication not
prescribed
(n = 550)
N % n % n %
M09: Other drugs for disorders of the musculo-skeletal system 02 0.13 02 0.21 00 0.00
N: Nervous system 397 26.14 183 18.09 214 38.91
N02: Analgesic drugs 367 24.16 157 16.20 210 38.18
N03: Antiepileptics 03 0.20 03 0.31 00 0.00
N05: Psycholeptics drugs 14 0.92 11 1.14 03 0.55
N06: Psychoanaleptics 11 0.72 10 1.03 01 0.18
N07: Other nervous system drugs 02 0.13 02 0.21 00 0.00
P: Antiparasitic products, insecticides and repellents 165 10.86 118 12.18 47 8.55
P01: Antiprotozoal drugs 130 8.56 92 9.49 38 6.91
P02: Anthelmintic drugs 35 2.30 26 2.68 09 1.69
R: Respiratory system 159 10.47 102 10.53 57 10.36
R01: Nasal preparations 45 2.96 26 3.45 19 2.68
R02: Throat drugs 03 0.20 03 0.31 00 0.00
R03: Drugs for obstructive airway diseases 09 0.59 07 0.72 02 0.36
R05: Cough and cold drugs 35 2.30 25 2.58 10 1.82
R06: Antihistamines for systemic use 64 4.21 41 4.23 23 4.18
R07/ Other respiratory system products 03 0.20 00 0.00 03 0.55
S: Sensory organs 30 1.97 27 2.79 03 0.55
S01: Ophthalmological drugs 27 1.78 25 2.58 02 0.36
S02: Otologicals 03 0.20 02 0.21 01 0.18
V: Various ATC structures 4 0.26 4 0.41 0 0.00
V06: General nutrients 4 0.26 4 0.41 0 0.00
Medication not identified 37 2.44 23 4.18 14 1.44
https://doi.org/10.1371/journal.pone.0221335.t003
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Discussion
This is one of the first studies performed in West Africa describing the use of non-HIV medi-
cations among PLHIV on ART. In summary, 48% of PLHIV reported using at least one non-
HIV medication, and 54% of them used non-prescribed drugs. The most reported classes of
non-HIV medication used were the nervous system class (26%) and the alimentary tract and
metabolism class (17%). Non-prescribed non-HIV medications represented 36% of 1,519 non-
HIV medications, of which 39% were analgesic medications. Factors associated positively with
the use of non-HIV medication were having a high level of school education, a monthly
income between 152 and 304 euros, using TCM products, having a poor perceived health sta-
tus and having a WHO stage II or III/IV. However, being treated in an HIV hinterland clinic
and using cotrimoxazole were factors negatively associated with the use of non-HIV
medication.
The proportion of PLHIV using non-HIV medications (48%) we observed was lower than
those observed in most of the previous studies in both high- [41–50] and low-income countries
[31, 34], where the proportions varied between 68% and 95%, distributed as follows: 68% in
Switzerland [46, 50], 75% in Canada [45], 82% in Spain [42], 83% in USA [43], 85% in Senegal
[31] 85% in USA [44], 87% in South Africa [34], 89% in Canada [41], 91% in Canada [47],
93% in USA [48] and 95% in Canada [49]. This difference might be explained by different rea-
sons. Older PLHIV face many aging-related diseases [51, 52]. Our population was younger
than those included in the high-income countries studies. Indeed, 32% [43, 47, 50] to 100%
[42] of patients from high-income countries were over 50 years old, whereas in our study, only
27% were over 50 years old. Third, in the studies in high-income countries, 79% [43, 48] to
100% [45] of participants had public or private drug insurance, whereas only 10% of our study
participants had such insurance, which may limit access to non-HIV medications.
One study conducted in Africa reported proportions of non-HIV medication users [31].
This was a retrospective study conducted in Senegal including 331 PLHIV who initiated ART
between 2009 and 2011 and were followed until March 2012. PLHIV in the first year of ART
initiation represented 43% of the participants. After a mean duration of 11.4 months on ART,
85% of patients received at least one prescription for a non-ART medication. In this study, the
most frequently prescribed non-ART medications were cotrimoxazole (78.9% of patients),
iron (33.2%), vitamins (21.1%) and antibiotics (19.6%).
Regarding non-HIV medication findings, in Coˆte d’Ivoire, before the availability of ART,
in a cohort study, Nombela et al. reported 58,776 medications prescribed among 592 PLHIV.
The most used classes of medication were the anti-infectious (32.8%) and pain medication
(22.9%) classes [32]. In our study, the most common non-HIV medications used by partici-
pants were from the nervous system class (26%), as in some studies conducted in high-income
countries [42, 47, 48]. However, we observed that the proportion of nervous system class medi-
cation users (24%) in our study was lower than the proportions observed in the USA (32%)
[44], (52% [48]), Spain (44% [42]) and Canada (58% [47]). This difference could be explained
by a greater diversity of therapeutic classes (antidepressants/antipsychotics/anxiolytics/analge-
sics) used in high-income countries, unlike in our study, where 96% of users of nervous system
medications took analgesics. Indeed, accessibility to nervous system classes other than analge-
sics is limited in low-resource countries [53]. Furthermore, mental health services are only
accessible in specialized health facilities.
The proportions of users of medications for the treatment of cardiovascular diseases and
diabetes in our study were 5% and 1%, respectively, which are lower than those found in high-
income countries (with the percentages of cardiovascular medication users being 43% [47],
26% [42], and 42% [44] and the percentage of diabetes medication users being 11% [44, 48]).
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Table 4. Associations between patient-related, health-related and treatment-related characteristics and use of at least one non-HIV medication (N = 1458).
Characteristics Use of at least one non-
HIV medication
Crude prevalence
ratios
95% Confidence
Intervals (CI)
P values Adjusted prevalence
ratios
95% CI P values
Yes No
Patient-related
Age (years)
< 50 518 74.4 552 72.4 0.96 [0.85–1.10] 0.40 0.90 [0.84–
1.09]
0.59
� 50 178 25.6 210 27.6 1 1 1 1
Sex
Men 173 24.9 208 27.3 1.07 [0.94–1.21] 0.30 1.12 [0.97–
1.29]
0.12
Women 523 75.1 554 72.7 1
HIV clinics
Hinterland 296 42.5 426 55.9 0.75 [0.68–0.84] <0.001 0.72 [0.64–
0.82]
<0.001
Abidjan 400 57.5 336 44.1 1
Have a significant other
Yes 362 52.0 364 47.8 1
No 334 48.0 398 52.2 0.91 [0.82–1.01] 0.10
Education
No school 184 26.4 270 35.4 1
Primary level 199 28.6 234 30.7 1.13 [0.97–1.32] 0.103 1.04 [0.89–
1.21]
0.62
Secondary school 249 35.8 221 29.0 1.31 [1.14–1.50] 0.0002 1.17 [1.02–
1.35]
0.026
> High school 94 9.2 37 4.9 1.56 [1.30–1.88] <0.0001 1.23 [0.99–
1.50]
0.055
Monthly Income in Euros
< 92 437 62.8 527 69.2 1 1
92–151 107 15.4 128 16.8 1.00 [0.86–1.17] 0.95 0.91 [0.77–
1.06]
0.24
152–304 92 13.2 56 7.3 1.37 [1.19–1.58] <
0.0001
1.31 [1.12–
1.53]
0.0006
� 304 52 7.5 38 5.0 1.27 [1.05–1.54] 0.01 1.11 [0.88–
1.41]
0.36
Don’t Know 8 1.1 13 1.7
Insurance coverage
Yes 88 12,6 57 7.5 1.31 [1.14–1.51] 0.0002
No 608 87.4 705 92.5 1
Health-related
Perceived Health Status
Poor 500 71.9 596 78.2 1.38 [1.23–1.55] <
0.0001
1.30 [1.16–
1.46]
<0.0001
At least acceptable 195 28.0 166 21.8 1
Missing data 1 0.1
Time since HIV diagnosis
(months)
96 12–
235
85 12–
270
� 120 498 71.5 598 78.5 0.83 [0.74–0.93] 0.0014
> 120 198 28.5 164 21.5
Initial CD4 count in cells/mm3;
< 200 334 48.0 351 46.0 1.004 [0.83–1.21] 0.96
(Continued)
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This difference could be explained by the fact that diagnosis of non-communicable diseases in
low-income countries is not routinely performed during HIV visits and by the low proportion
of old PLHIV in our study. Therefore, we hypothesize that in our study, PLHIV with poten-
tially non-communicable diseases may suffer from cardiovascular disease or diabetes, but they
are not aware of their condition because they do not have access to diagnostics. The users of
sex hormones and modulators of the genital system represented 9% [47] and 19% [44] in the
PLHIV populations of high-income countries. In our study, only 0.9% used these drugs.
The use of a prescription medication without a prescription from a health professional was
observed in our PLHIV population. Antibiotics and anti-malaria medications were used with-
out prescription by 3.0% and 2.5% of participants, respectively. Individuals using those drugs
without a prescription have likely not been exposed to appropriate diagnostic tests. The misuse
of antibiotics or malaria medications can increase the risk of resistance to these medications
and of drug-drug interactions [47, 54].
Seven factors were associated with the use of non-HIV medications. Some of these factors,
such as WHO advanced clinical stage [31] and high level of education and high income [19],
are in line with those that have been reported in previous studies. In our study, we observed
that PLHIV living in Abidjan had higher incomes and access to non-HIV medications com-
pared with PLHIV from the hinterland HIV clinics.
This study provides insight on the use of non-HIV medication by PLHIV on ART in West
Africa. To our knowledge, this is the first study conducted in Africa that describes the extent
to which non-HIV medications used were prescribed or not.
Table 4. (Continued)
Characteristics Use of at least one non-
HIV medication
Crude prevalence
ratios
95% Confidence
Intervals (CI)
P values Adjusted prevalence
ratios
95% CI P values
Yes No
200–349 186 26.7 207 27.2 0.97 [0.78–1.19] 0.80
350–499 96 13.8 122 16.0 0.90 [0.72–1.14] 0.40
� 500 67 9.6 71 9.3 1
Missing data 13 1.9 11 1.5
WHO HIV clinical stage
I 219 31.5 316 41.5 1
II 265 38.0 256 33.6 1.24 [1.09–1.42] 0.0013 1.24 [1.08–
1.41]
0.0017
III or IV 205 29.5 205 23.0 1.32 [1.15–1.81] <0.0001 1.22 [1.06–
1.40]
0.005
Missing data 0 00.0 1 00.1
Data not available 7 01.0 14 01.8
Treatment-related
Use of cotrimoxazole
No 462 66.4 461 60.5 1
Yes 234 33.6 301 39.5 0.87 [0.78–0.98] 0.022 0.77 [0.69–
0.87]
<0.0001
Use of traditional and
complementary products
Yes 407 58.5 369 48.4 1.24 [1.11–1.38] 0.0001 1.22 [1.10–
1.37]
<0.0001
No 289 41.5 393 51.6 1
https://doi.org/10.1371/journal.pone.0221335.t004
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Our study has some limitations. First, we could not include patients who did not show up
for their HIV follow-up. It is possible that these people were sicker than our participants.
Therefore, we may have underestimated the proportion of non-HIV medication users. Second,
the use of non-HIV medication was self-reported, which is susceptible to a memory bias.
Therefore, the proportion of people using non-prescribed non-HIV medications may have
been underestimated. Similarly, PLHIV who forgot their medications or prescriptions at home
may have under-reported the use of non-HIV medications. If these medications were not actu-
ally medications, the proportion of non-HIV medications would be underestimated. More-
over, answers to questions related to income and health status perception may have suffered
from social desirability bias. Next, since our study was conducted in only four regions in Coˆte
d’Ivoire, our results are not generalizable to the entire population of PLHIV on ART in Coˆte
d’Ivoire.
Conclusion
In this study, we observed that approximately 50% of PLHIV on ART for at least one year used
a non-HIV medication. More than half of them used non-HIV medications that were not pre-
scribed. The results of this study suggest that healthcare professionals should pay attention to
the needs of PLHIV in terms of non-HIV medications, particularly for patients living in Abi-
djan and those who are not using cotrimoxazole.
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